We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
76
Illumina
ILMN
$29B
$2.49M 0.06%
20,223
-2,717
-12% -$357K
KMTS
77
Kestra Medical Technologies
KMTS
$1.64B
$2.3M 0.05%
115,590
-165
-0.1% -$3.89K
OMDA
78
Omada Health Inc
OMDA
$1.46B
$1.99M 0.05%
157,938
-19,959
-11% -$276K
BBIO icon
79
BridgeBio Pharma
BBIO
$15.6B
$1.88M 0.04%
25,377
+1,266
+5% +$91.8K
BNTX icon
80
BioNTech
BNTX
$23.2B
$1.85M 0.04%
20,851
-22,904
-52% -$2.35M
RPRX icon
81
Royalty Pharma
RPRX
$26.1B
$1.84M 0.04%
38,296
+25,095
+190% +$1.1M
SPY icon
82
State Street SPDR S&P 500 ETF Trust
SPY
$813B
$1.76M 0.04%
2,700
-400
-13% -$272K
INSM icon
83
Insmed
INSM
$26.9B
$1.64M 0.04%
10,034
-3,881
-28% -$597K
MDGL icon
84
Madrigal Pharmaceuticals
MDGL
$11.7B
$1.59M 0.04%
3,040
+156
+5% +$74.5K
MASI
85
DELISTED
Masimo
MASI
$1.56M 0.04%
8,753
-88,532
-91% -$13.9M
PTGX icon
86
Protagonist Therapeutics
PTGX
$10B
$1.52M 0.04%
14,447
-2,096
-13% -$186K
UTHR icon
87
United Therapeutics
UTHR
$21.4B
$1.23M 0.03%
2,077
-1,818
-47% -$905K
ONC
88
BeOne Medicines Ltd
ONC
$39.3B
$1.13M 0.03%
3,812
+1,922
+102% +$622K
PHR icon
89
Phreesia
PHR
$760M
$1.1M 0.03%
130,992
-52,221
-29% -$691K
ADPT icon
90
Adaptive Biotechnologies
ADPT
$3.95B
$1.06M 0.03%
76,181
-221,909
-74% -$3.54M
BMY icon
91
Bristol-Myers Squibb
BMY
$131B
$1.03M 0.02%
17,038
-50,044
-75% -$2.92M
EHC icon
92
Encompass Health
EHC
$12.2B
$951K 0.02%
9,829
-9,260
-49% -$950K
NAMS icon
93
NewAmsterdam Pharma
NAMS
$3.19B
$885K 0.02%
27,661
-8,675
-24% -$283K
AAPL icon
94
Apple
AAPL
$4.46T
$843K 0.02%
3,320
– –
BLLN
95
BillionToOne Inc
BLLN
$4.39B
$833K 0.02%
10,554
-35
-0.3% -$2.87K
MLYS icon
96
Mineralys Therapeutics
MLYS
$2.28B
$796K 0.02%
29,374
+9,548
+48% +$280K
EQNR icon
97
Equinor
EQNR
$97.1B
$742K 0.02%
+17,573
New +$530K
XOM icon
98
ExxonMobil
XOM
$661B
$741K 0.02%
+4,370
New +$638K
BP icon
99
BP
BP
$110B
$735K 0.02%
+15,644
New +$613K
SHEL icon
100
Shell
SHEL
$251B
$729K 0.02%
+7,844
New +$634K
2 3
4
5 6

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.